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1. Introduction  
In this chapter, cutaneous metastases from malignant melanoma will be analyzed from a 
clinical and a prognostic point of view.  
This non rare condition is often distressing for the patient, as cutaneous lesions increase 
progressively in number and size and are frequently worsened by ulceration, bleeding and 
pain. 
After a general introduction about the incidence of cutaneous involvement in melanoma 
natural history, clinical classification of skin metastases will be provided. Then, the impact 
of cutaneous localizations on prognosis will be evaluated. In the last paragraph, the different 
therapeutic options for the management of patients with loco-regional or diffused cutaneous 
metastases will be reviewed.  
2. Epidemiology 
Skin metastases from solid tumor are not rare. They affect an estimated percentage of patients 
ranging from 0.7 to 9% in several literature series (Spencer & Helm 1987, Lookingbill, Spangler 
& Helm 1993, Schwartz 1995, Hu et al. 2008), in the late phases of disease progression or, in 
more than 7% of patients, as first sign of disseminated disease (Lookingbill, Spangler & Helm 
1993, Rosen 1980). Breast cancer is the most commonly involved tumor, accounting for more 
than 60% of cases of cutaneous spread, followed by colon carcinoma (Krathen, Orengo & 
Rosen 2003). Moreover, cutaneous metastatic disease is commonly seen with cancer of the 
lung, kidney and ovary and with sarcoma, lymphoma or leukemia. 
As expected, tumor types are differently distributed among the two genders: lung, colon 
and head and neck tumours together with melanoma account for the majority of skin 
metastases in males; whereas, breast cancer is the most common neoplasm related to the 
development of cutaneous secondary lesions in females (Hu et al 2008). 
Focusing on melanoma, skin metastases represent a relatively frequent event in the natural 
history of the disease and can develop in early as well as in late stage of disease. Cutaneous 
or subcutaneous lesions arise in 10-17% of patients affected by melanoma and almost the 
50% of patients with metastatic disease develops skin involvement (Lookingbill, Spangler  & 
Helm 1993, Schwartz 1995, Krathen, Orengo & Rosen 2003).  
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No specific clinical or histological characteristics were found in patients with cutaneous 
metastases from melanoma if compared to those with visceral localizations (Savoia et al 
2009). However, known risk factors related to prognosis impact on the metastatic melanoma 
potential.  
3. Classification 
On the basis of the distance from the primary melanoma, skin metastases are described as 
local recurrences, in transit disease or distant metastases. 
True local recurrences are defined as the reappearance of melanoma in -or contiguous with- 
an excision scar or a graft and bearing an in situ component (Olsen et al 1970; Brown & 
Zitelli 1995). The prognosis of local recurrence defined strictly in this way is much better 
than that associated with in transit disease and 5-year survival rate is related only to the 
thickness of the primary melanoma. These recurrences are in fact considered as a result of a 
uncompleted resection of primary melanoma, and are for this reason becoming rare.  
In-transit disease (satellitosis) indicates cutaneous or subcutaneous disease between the 
primary site and the regional lymph nodes. Satellite nodules and in-transit disease are 
associated with worse prognosis (super imposable to a melanoma with nodal metastases; 
stage III disease), and the distance of cutaneous deposits from the primary site has no 
prognostic significance (Balch et al 2009). 
Distant cutaneous metastases are defined as tumour lesions that grow in any skin site over 
the regional lymph nodes. The presence of any distant metastases delineates a stage IV 
disease, even if patients with sole distant skin metastases (and normal serum LDH levels) 
have a relatively better prognosis if compared with those of other metastatic patients (Balch 
et al 2009). Obviously, distant skin melanoma localization can appear together with or in 
absence of other visceral metastases. Stage and prognosis vary according to AJCC 
classification as shown in table 1 (Balch et al 2009). 
 
Clinical Staging Pathological Staging
0 Tis N0 M0 0 Tis N0 M0 
IA T1a N0 M0 IA T1a N0 M0 
IB T1b N0 M0 IB T1b N0 M0 
 T2a N0 M0 T2a N0 M0 
IIA T2b N0 M0 IIA T2b N0 M0 
 T3a N0 M0 T3a N0 M0 
IIB T3b N0 M0 IIB T3b N0 M0 
 T4a N0 M0 T4a N0 M0 
IIC T4b N0 M0 IIC T4b N0 M0 
III any T N 1-3 M0 IIIA T1-T4a N1a/2a M0 
  IIIB T1-T4b N1a/2a M0 
  T1-T4a N1b/2b M0 
  T1-T4a/b N2c M0 
  IIIC T1-T4b N1b/2b/2c M0 
  any T N3 M0 
IV any T any N M 1 IV any T any N M 1 
Table 1. Clinical and pathological staging, AJCC 2009. 
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4. Clinical features 
Skin metastases from melanoma can arise as single or multiple nodules. The most common 
presentations of cutaneous metastatic disease are brown to black or skin colored papules 
and nodules, sometimes ulcerated. In the majority of these cases cutaneous metastases were 
correctly identified by the clinician before the pathologic diagnosis was given; dermoscopy 
could help in diagnosis, even if skin melanoma metastases have often aspects that are  
indistinguishable from the characteristic pattern of blue nevi (Carlos-Ortega, de Oca-
Monroy & Isyta-Morales 2008). Epidermotropic melanoma metastases are histopatologically 
characterized by aggregates of atypical melanocytes within the dermis with thinning of the 
epidermis. Usually there is no lateral extension of atypical melanocytes within the epidermis 
beyond the concentration of the metastases on the dermis. Metastases differs from primary 
melanoma by the absence of inflammatory infiltrate and junctional activity, even if a 
prominent  lymphocytic infiltrated can be sometimes observed. In few cases metastatic cells 
are small and nevoid, with few or any mitoses and differentiation from compound nevi is 
difficult (Elder E et al, 2005. Tumours and Cysts in dermis and Subcutis, in: Lever’s 
histopathology of the skin. Lippincott Williams&Wilkins, Philadelphia). 
Less frequently, a wide morphological spectrum of lesions has been described, including 
erythematous patches or plaques, inflammatory erysipela-like lesions, diffuse sclerodermiform 
lesions with indurations of the skin (‘‘en cuirasse’’ metastatic carcinoma), telangiectatic 
papulovesicles, purpuric plaques mimicking vasculitis, and alopecia aerate-like scalp lesions 
(Saeed, Keehn & Morgan 2004, Sarya et al 2007). In these cases, clinical diagnosis could be 
more challenging and metastases can be suspicious for benign entities (Figure 1). 
 
 
Fig. 1. Clinical features of local recurrences that are defined as the reappearance of 
melanoma in or contiguous with an excision scar or graft and bearing an in situ component. 
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Moreover, there are also rare cases of so-called zosteriform metastases, with vesicobullous 
herpetiform lesions or papules and nodules distributed along one or more dermatomes. A 
previous Varicella Zoster Virus (VZV) infection or widespread lymphatic obstruction by 
tumor cells can justify the zosteriform pattern (Figure 2).  
 
 
Fig. 2. Zosteriform metastases among thoracic dermatomes. 
However, zosteriform metastases, as well as the rare skin metastases occurring on skin graft 
donor site, could be explained as a Koebner phenomenon (Savoia et al 2009, Marenco et al 
2009). 
From a clinical point of view, if bleeding and super-infection are not present, superficial skin 
metastases are usually asymptomatic, even if patients frequently report localized pain and 
paresthesiae anticipating the onset of clinically evident cutaneous lesions; these symptoms 
are related to oedema and mechanical stress on the near tissues and usually disappear in a 
few days. On the other hand, when subcutaneous lesions grow deep infiltrating muscles or 
nerves become very painful. The management of pain in these cases could be difficult and 
requires a multidisciplinary approach. 
As mentioned earlier, bleeding and super-infections are the most frequent complications of 
skin metastases and can significantly impact on the patient's quality of life (Kaheler, 
Egeberts & Hauschild 2010). These complications can also compromise general conditions. 
Massive bleeding from cutaneous metastases could become life threatening; sepsis related to 
the bacterial dissemination of infected metastases represents an uncommon but not rare 
event, that lead to septic shock and death (Figure 3).  
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Fig. 3. Infected diffuse metastases from malignant melanoma 
5. Pattern of cutaneous localizations 
Cutaneous secondary lesions can occur on all anatomic sites, with skin metastases from 
other solid tumours more frequently found on the head, neck, anterior chest and abdomen, 
whereas lower extremities are rarely involved (Schwartz, 1995).  Conversely, skin metastases 
from melanoma are more frequently observed on the back in men and on the lower limbs in 
women. These different patterns of cutaneous localizations among sex can be explained by 
the fact that in more than 30% of cases, secondary cutaneous localizations occur in the same 
anatomic area of the primary (Savoia et al 2009). 
6. Clinical course and prognosis 
In more than half of the cases, skin represents the first site of metastatic involvement after 
the primary melanoma diagnosis. In about one third of cases, patients develop skin 
involvement after evidences of regional lymph nodal metastatic disease.  
The finding of concomitant distant cutaneous, visceral and nodal metastases account for 
more than 10% of cases, whereas skin involvement after visceral dissemination is rare, and 
occurs only in about the 3% of patients (Savoia et al 2009). 
Cutaneous metastases are loco regional in nearly 80% of cases, whereas distant metastases 
were documented in the remaining 20% of patients. A different pattern of cutaneous 
metastases was related to the time of onset: when cutaneous metastases arise as the first site 
of relapse, there is a significant higher percentage of locoregional localizations, whereas 
distant skin involvement was more frequently observed after visceral involvement. No 
significant differences were found between patients with regional and those with distant 
metastases regarding to the known risk factors, such as Breslow thickness, Clark level, 
histotype of the primary melanoma and ulceration (Savoia et al 2009).  
It is noteworthy that in patients with distant metastases, primary melanomas arose 
predominantly at trunk and back, whereas patients with cutaneous loco-regional spreading 
were affected mainly by primary located at leg and foot. As we know, loco-regional 
metastases develop as a result of tumour cell embolization in the dermal lymphatic vessels 
between the primary tumour site and the draining regional lymph node basin; lymphatic 
stasis to lower limbs consequent to nodal dissection represents an additional risk factor for 
cutaneous locoregional dissemination.  
In contrast, the correlation between disseminated skin lesions and primary melanoma 
located to the trunk could be explained by the fact that the lymph drainage of this region is 
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not strictly dependent on a single station, but it could be resulted from more than one 
lymphatic basin, together with a possible role of haematogenous spreading. 
Disease free survival evaluated from the first melanoma diagnosis varies in relation to the 
first site of metastatization. In our experience, loco regional cutaneous relapses develop 
early, but show a very late progression to visceral disease. On the contrary, patients with 
disseminated skin lesions as first site of relapse had a longer disease free interval from the 
first diagnosis but a shorter time to progression to visceral metastases (Savoia et al 2009).  
7. Treatment and clinical management 
The choice of the modality of treatment for cutaneous melanoma metastases depends on 
several factors, including location and number of lesions, presence of systemic involvement, 
age and general health conditions of patients. Moreover, the prognostic differences between 
patients with loco-regional and distant skin metastases justify different approaches in their 
clinical management.  
Important therapeutic options including surgery, isolated limb perfusion, local or systemic 
chemo- and immuno-therapy and radiotherapy are discussed in detail below. 
7.1 Surgery 
Surgery is the gold standard and represents the most effective treatment for limited in-
transit disease, when technically feasible. It is an adequate treatment when the lesions are 
relatively small and clustered in a reasonable circumscribed area. Primary melanoma should 
be excised widely with a 1-2 cm margin depending on Breslow thickness, whereas wide 
surgical margins are unnecessary for the treatment of cutaneous metastases. Usually, 
metastases are clearly demarcated from the surrounding normal dermis and overlying 
epidermis and the better approach is the complete macroscopical excision of the lesion. 
When microscopical involvement of margins is documented, reintervention is not 
mandatory (Hoekstra, 2008).  
If technically possible, direct wound closure is to prefer; the second choice is represented by 
skin graft, because plastic surgical reconstruction can affect the lymphatic drainage pattern.  
Palliative treatment should be considered when results in the control of local complications 
(e.g. bleeding) and/or in a consistent quality of life improvement. 
Amputation should be only considered as palliation for imminent exsanguinating 
haemorrhage or fungation unacceptable for the patient. 
7.2 Isolated limb perfusion 
Isolated limb perfusion (ILP) -firstly described by Creech and Krementz in 1958- can deliver 
high doses of cytotoxic agents to a limb, minimizing systemic toxicity. The dose received 
regionally can be up to tenfold higher than the systemic mean tolerated dose. Isolated limb 
perfusion is widely indicated for patients with advanced or recurrent in-transit disease, 
showing a complete response rate around the 50% in the majority of the published series, 
with an overall response rate up to 80% (Lens & Dawes 2003, Rossi et al 2010). On the 
contrary, the role of isolated limb perfusion as adjuvant therapy is still debated (Hoeckstra 
2008). The tumour response after perfusion is the only demonstrated prognostic factor 
affecting local control of the disease and overall survival (Rossi et al 2010). 
The usual agent employed is melphalan, with or without tumour necrosis factor (TNF); TNF 
increases response rate thanks to its selective disruption of the tumour microvasculate, with 
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a consequent ischemic damage of melanoma cells, even if seems not to influence the long 
term local control (Di Filippo et al 2006). Dacarbazine is less effective when administered 
regionally; other combinations of cytostatics (dactinomycin, nitrogen mustard, vindesine, 
thio-TEPA) have also been proposed but the published series are too small to give absolute 
conclusions (Daryanani et al 2000, de Wilt et al 2000, Hoeckstra 2008). Hyperthermia, with 
temperature between 39° to 41° act sinergically with high dose chemotherapy, even if can 
exacerbate loco regional toxicity (Hoeckstra 2008). 
General anesthesia is required. However, age does not represent a contraindication to ILP. 
Systemic side effects, due to drug releasing into the systemic circulation are rare and mainly 
represented by nausea, vomiting and mild bone marrow suppression. Local toxic reactions 
are more frequently described and ranges from mild erythema to deep tissue inflammation; 
nearly 25% of patients develop neuropathy or pain, whereas chronic edema is usually 
related to lymphoadenenctomy (Bonifati et al 2000, Rossi et al 2002). 
7.3 Electrochemotherapy 
Recently, electrochemotherapy (ECT) has been proposed as a new treatment modality for 
skin metastases of different malignancy, including melanoma. ECT enhances membrane 
permeability by electric pulses thus permitting a major drug delivery in neoplastic cells and 
a better cytotoxic effect.  
Bleomycin and cisplatin are the drugs more frequently used in ECT with an increased 
efficacy up to 8.000-fold for bleomicyn, and up to 80-fold for cisplatin  (Gaudy et al 2006). 
The ECT technique requires only a regional anesthesia or mild general sedation with a lower 
duration if compared to isolated limb perfusion. With respect to ILP, ECT shows a minimal 
systemic toxicity; treatment is generally well tolerated; side effects were mainly represented 
by erythema and edema at the site of treated lesions, superficial erosions, scars and 
permanent marks from the electrodes (Quaglino et al 2008). Thus ECT can be performed 
also in patients with major co morbidities.  
The first large study about effectiveness of ECT in melanoma treatment, was the multi 
center European Standard Operating Procedure of Eettrochemoterapy (ESOPE), based on 
the new CliniporatorTM Elettric Pulse Generator; this study enrolled twenty melanoma 
patients, with an overall response rate of more than 20% (Marty et al 2008). Several papers 
recently published confirm these encouraging results of ECT in the control of skin 
metastases (Campana et al 2009, Moller  et al 2009). In our experience, the global response 
rate was of 79.4, with a percentage of complete remissions of 23.2%(Quaglino et al 2008); 
complete response was defined in accordance World Health Organiziation (WHO) 
guidelines as the total clinical disappearance of the tumor (WHO. From Handbook for 
Reporting Results of Cancer Treatment, vol 48;  pp 22-27. Geneva, 1997). 
The lesion size was the most predictive parameter for response; response rate for larger 
lesions was significantly lower. Moreover, a second limit is represented by the possible 
relapse of new lesions on untreated areas: ECT represent in fact a local treatment. However, 
it is possible to repeat ECT, both on new metastases in untreated areas and on already 
treated lesions with a previous partial remission or no changes. In our experience, new 
responses were obtained in about 60% of retreated lesions. 
Appropriate dressing should be performed with the aim to control ulceration of cutaneous 
tumours, local infectious complications and to ensure an acceptable quality of life. 
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The effectiveness of radiotherapy in the treatment of melanoma metastases is still debated. 
A poor response was historically observed on in vitro cultures from melanoma cells treated 
with external-beam radiation (Barranco, Romsdahl & Humphrey 1971). So, radiotherapy 
was mainly used as palliation when disease was too extensive for surgery and other 
modalities of treatment were inadvisable or ineffective in stage III and IV melanoma 
patients. However, a retrospective review (Fenig et al 2009) showed a 52% response rate in 
stage IV patients who received radiotherapy with palliative intent and others studies (Sause 
et al 1991; Seegenschmeid et al 1999) demonstrated an overall response rate ranging from 60 
to 79% for stage III disease. Moreover, disease-free and overall survival seems to be 
significant longer in patients who received radiotherapy (Olivier et al, 2007). 
7.5 Chemotherapy 
Usually, chemotherapy plays a role in the treatment of stage IV melanoma patients with 
visceral metastases. Regarding cutaneous metastases, chemotherapy can be used in patients 
with wide spread skin lesions not eligible for local treatments, with or without a 
concomitant visceral involvement. 
Chemotherapy could be used also in stage III, when other loco-regional treatments have 
failed or are technically not feasable (e.g. cutaneous lesions diffused at trunk or back). 
The global response rate is less than 25% for single agent treatment. The gold standard is 
still represented by Dacarbazine; new molecules as Temozolomide and Fotemustine showed 
a super imposable disease-free and overall survival, with major toxicity (Middelton et al, 
2000). Combination regimens or chemo-immunotherapy give higher response rate but also 
more severe side effects. However, response to chemo-immunoterapy is not related to 
statistically significant benefit in term of overall survival when compared with a single-
agent treatment.  
Recently, Ipilimumab, a human anti-CTLA4 monoclonal antibody showed objective 
responses or disease stabilization in patients with advanced melanoma (O'Day et al, 2010). 
No data about the effectiveness of Ipilimumab in the treatment of cutaneous metastases are 
available, even if several studies are ongoing. 
The response rate for in transit metastases treated with dacarbazine is 15-20%; the majority 
of the responses are partial with a median response duration less than 6 months. 
Chemoimunotherapy showed also no survival benefit (Hoekstra 2008).    
Finally, the clinical efficacy of RAF inhibitors in BRAF mutated melanoma patients are 
under evaluation after some encouraging preliminary report; a phase I study on patients 
with both disseminated cutaneous and visceral metastases reported an 81% of clinical 
responses in patients treated with selective BRAF inhibitor, with a median time to 
progression of 6-9 months (Flaherty, 2010). 
7.6 Others 
7.6.1 Laser ablation 
Patients with small (<2 cm) and superficial lesions who are not suitable for isolated limb 
perfusion, ECT or other conventional modalities of treatment can be considered for carbon 
dioxide (CO2) laser ablation. This therapy is minimally invasive: only local anesthesia is 
required and the resultant defect does not require surgical closure but can be covered with a 
dressing until secondary healing (Lingam & McKay, 1996; Gibson, Byrne & Mc Kay, 2004). 
www.intechopen.com
Cutaneous Metastases from Malignant Melanoma:  
Clinical Features and New Therapeutic Perspectives 
 
11 
So, can be considered a minimally invasive and effective method of palliation; the role as 
first line treatment is still debated, in fact the technique can be used to treat only visible and 
superficial lesions, while deep subcutaneous metastases, large volume lesions and 
microscopic disease can not be treated with laser ablation (Gimbel, Delman & Zager, 2008).  
7.6.2 Cryosurgery  
This technique uses temperatures from -50°C to -60°C (with nitrogen spray) to obtain direct 
tissue destruction. The heat transfer results in vascular stasis, ice crystal and disruption of 
cell membranes, Ph changes, hypertonic damage and thermal shock that lead to tissue 
damage and necrosis. Low temperature causes the development of a bulla and a secondary 
healing with a scar.  After the introduction of laser ablation and ECT, cryosurgery is less 
frequently used in the treatment of cutaneous metastases from melanoma (Hoekstra, 2008). 
7.6.3 Intralesional therapy  
The intralesional injection of bacillus Calmette-Guérin (BCG) was the first immunotherapy 
used in the local treatment of cutaneous metastases from melanoma. This procedure was 
accompanied by sever complications such as ulceration, skin necrosis, and superinfection 
without significative improvement of lesions treated (Tan & Ho, 1993).  Other drugs such as 
IL-2, INF alpha and dinitrochlorobenzene, with or without sistemic dacarbazine, were more 
recently used as intralesional therapy (Radny et al, 2003; Strobbe et al, 1997); results are still 
debating and further investigations are necessary. Encouraging results regarding high-dose 
intratumoral IL-2 administration in melanoma patients with cutaneous secondarities has 
been reported (Weide et al, 2010): a complete local response was described in more than 60% 
of melanoma patients and seemed to be associated with an increased responses to 
subsequent chemotherapies. Recently, phase I studies confirmed the safety and an enhanced 
immune response for intralesional injection of Allovectin in metastatic melanoma patients. 
Unfortunately, phase II studies showed a complete response in only the 3.1% of treated 
patients, with an overall response rate of 11.8% and a median time-to-progression of 1.6 
months (Beidikan et al, 2010).  
Rose bengal has been proposed as a possible intralesional treatment, with an objective 
response rate ranging from 27 to 69%, related to the dose of injection (Thompson, Hersey & 
Wachter, 2008). Sistemic toxicity is low, even if phototoxic reactions have been described. 
An interesting therapeutic option is represented by topical imiquimod. It enhances the 
immune system activity leading to an induction of melanoma-specific cytotoxic T-cells by 
cross presentation of melanoma antigen by dendritic cells. Partial remission of locoregional 
cutaneous metastases treated with imiquimod was demonstrated (Wolf, Richtig, Kopera & 
Kerl H, 2004). 
8. Conclusions 
Skin metastases from melanoma are a frequent finding in the natural history of the disease 
with various clinical, morphological and histopathologic backgrounds. The presence of 
progressively increasing metastases is often distressing for the patient, and ulceration, 
bleeding and super-infections can negatively impact on the life-quality. To date, many 
treatments are available for the clinical management of these lesions. Thus, clinicians should 
be informed about the prognostic implications and the therapeutic options in order to 
choose the best cost-effectiveness treatment modality. 
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